Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease: A Randomized, Double-Blind, Sham-Controlled Clinical Trial

NCT07891650 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07891650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease: A Randomized, Double-Blind, Sham-Controlled Clinical Trial
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2027
Enrollment
160 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral small vessel disease, vascular cognitive impairment

Arms

As registered; 2 arms.

  • Active Personalized Intermittent Theta Burst Stimulation ExperimentalActive Personalized Intermittent Theta Burst Stimulation

    Participants will receive active personalized intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex, with the target individualized using resting-state functional MRI and neuronavigation. Treatment will last 24 weeks: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24. Each session will deliver 1,800 pulses at 80-100% of the resting motor threshold, adjusted according to tolerability, with 50-60 minutes between sessions.

  • Sham Personalized Intermittent Theta Burst Stimulation Sham comparatorSham Personalized Intermittent Theta Burst Stimulation

    Participants will receive sham stimulation at the individualized left dorsolateral prefrontal cortex target using a dedicated sham coil or sham mode. Sham stimulation will mimic the sounds, vibration, and procedures of active treatment without delivering effective magnetic stimulation. The schedule will match the active group: four sessions per day for five consecutive days in week 1, followed by four sessions on one treatment day each week during weeks 2-24, with 50-60 minutes between sessions.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 24 Baseline and week 24 (end of treatment)

    The Montreal Cognitive Assessment (MoCA) assesses global cognitive function. Total scores range from 0 to 30, with higher scores indicating better cognitive function. Change will be calculated as the week 24 total score minus the baseline total score. A positive change indicates improvement.

Lead sponsor's other trials

Xuanwu Hospital, Beijing, most recent start first.

Similar trials

Same condition (Cerebral Small Vessel Diseases) and phase, most recent start first.